Variation of Genes Controlling Carbohydrate and Lipid Metabolism

Obesity Clinical Trial

— CMgene  

Official title:

Variation of Genes Controlling Carbohydrate and Lipid Metabolism

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03310502
• Other study ID #: CMgene
• Status: Recruiting
• Start date: April 17, 2002
• Est. completion date: December 31, 2024

Study information

• Verified date: October 2021
• Source: Turku University Hospital
• Contact: Pirjo R Nuutila, MD, PhD
• Phone: +35823131868
• Email: pirnuu[@]utu.fi
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Aim of the study is to investigate genes regulating glucose and lipid metabolism in subjects whose glucose metabolism, lipid metabolism, blood flow, or body fat distribution has been measured using positron emission tomography (PET), magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS) or computed tomography (CT) as part of their previous participation in clinical trials conducted at Turku PET Centre. By combining information from PET, MRI, CT, proteomics, metabolomics and genetics analyses we aim to find connection between genetic variation and metabolic and cardiovascular disease.

Description:

The data is collected as a separate part of the clinical imaging study protocols using a separate inform consent approved by the local ethics committee. The participation for this study consists of drawing whole blood, serum and plasma samples for genetics, proteomics and metabolomics analyses. The results from these studies are combined with baseline data from the original clinical imaging studies to find connections between genetic variation, metabolism, blood flow and body fat distribution in a cross-sectional setting.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 2050
• Est. completion date: December 31, 2024
• Est. primary completion date: December 31, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Previous participation of studies measuring glucose metabolism, lipid metabolism, bloow flow and adiposity at Turku PET Centre Exclusion Criteria: -

Related Conditions & MeSH terms

• Cardiovascular Diseases
• Diabetes Mellitus, Type 2
• Insulin Resistance
• Lipid Metabolism Disorders
• Metabolic Diseases
• Obesity
• PreDiabetes

Locations

Country	Name	City	State
Finland	Turku PET Centre (Turku University Hospital)	Turku

Sponsors (4)

Lead Sponsor	Collaborator
Turku University Hospital	Kuopio University Hospital, University of Eastern Finland, University of Turku

Country where clinical trial is conducted

Finland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Skeletal muscle insulin sensitivity	Skeletal muscle glucose uptake during euglycemic-hyperinsulinemic clamp (µmol/kg tissue/min)	Baseline
Secondary	Whole body insulin sensitivity	Whole body glucose uptake during euglycemic-hyperinsulinemic clamp (µmol/kg body weight/min)	Baseline
Secondary	Visceral adipose tissue insulin sensitivity to glucose uptake	Visceral adipose tissue glucose uptake during euglycemic-hyperinsulinemic clamp (µmol/kg tissue/min)	Baseline
Secondary	Abdominal subcutaneous adipose tissue insulin sensitivity to glucose uptake	Abdominal subcutaneous adipose tissue glucose uptake during euglycemic-hyperinsulinemic clamp (µmol/kg tissue/min)	Baseline
Secondary	Brown adipose tissue insulin sensitivity	Brown adipose tissue glucose uptake during euglycemic-hyperinsulinemic clamp (µmol/kg tissue/min)	Baseline
Secondary	Brown adipose tissue glucose uptake during cold exposure	Brown adipose tissue glucose uptake during cold exposure (µmol/kg tissue/min)	Baseline
Secondary	Insulin sensitivity of adipose tissue lipolysis	Plasma free fatty acid concentration during euglycemic-hyperinsulinemic clamp (mmol/l)	Baseline
Secondary	Myocardial insulin sensitivity	Myocardial glucose uptake during euglycemic-hyperinsulinemic clamp (µmol/kg tissue/min)	Baseline
Secondary	Liver insulin sensitivity to glucose uptake	Liver glucose uptake during euglycemic-hyperinsulinemic clamp (µmol/kg tissue/min)	Baseline
Secondary	Endogenous glucose production	Endogenous glucose production during euglycemic-hyperinsulinemic clamp (µmol/kg body weight/min)	Baseline
Secondary	Brain insulin sensitivity to glucose uptake	Brain glucose uptake during euglycemic-hyperinsulinemic clamp (µmol/kg tissue/min)	Baseline
Secondary	Abdominal subcutaneous adipose tissue mass	Abdominal subcutaneous adipose tissue mass (kg)	Baseline
Secondary	Visceral adipose tissue mass	Visceral adipose tissue mass (kg)	Baseline
Secondary	Liver fat content	Liver fat percentage (%)	Baseline
Secondary	Myocardial fatty acid uptake	Myocardial fatty acid uptake at fasting state (µmol/kg tissue/min)	Baseline
Secondary	Liver fatty acid uptake	Liver fatty acid uptake at fasting state (µmol/kg tissue/min)	Baseline
Secondary	Abdominal subcutaneous adipose tissue fatty acid uptake	Abdominal subcutaneous adipose tissue fatty acid uptake at fasting state (µmol/kg tissue/min)	Baseline
Secondary	Visceral adipose tissue fatty acid uptake	Visceral adipose tissue fatty acid uptake at fasting state (µmol/kg tissue/min)	Baseline
Secondary	Brown adipose tissue fatty acid uptake at fasting state	Brown adipose tissue fatty acid uptake at fasting state (µmol/kg tissue/min)	Baseline
Secondary	Brown adipose tissue fatty acid uptake during cold exposure	Brown adipose tissue fatty acid uptake at cold exposure (µmol/kg tissue/min)	Baseline
Secondary	Skeletal muscle fatty acid uptake	Skeletal muscle fatty acid uptake at fasting state (µmol/kg tissue/min)	Baseline
Secondary	Coronary flow reserve	Ratio of myocardial blood flow maximum at stress (ml/g/min) vs. myocardial blood flow at rest (ml/g/min)	Baseline